Related references
Note: Only part of the references are listed.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Matthew J. Page et al.
PLOS MEDICINE (2021)
Socioeconomic Impact of RSV Hospitalization
Michal Young et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Mapping PedsQLTM scores onto CHU9D utility scores: estimation, validation and a comparison of alternative instrument versions
Rohan Sweeney et al.
QUALITY OF LIFE RESEARCH (2020)
Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016
Brian Rha et al.
PEDIATRICS (2020)
Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15
Carmen S. Arriola et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)
Impact of Respiratory Syncytial Virus-Confirmed Hospitalizations on Caregivers of US Preterm Infants
Robin M. Pokrzywinski et al.
CLINICAL PEDIATRICS (2019)
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review
Stephen Mac et al.
PEDIATRICS (2019)
Valuing Health Status in the First Year of Life: The Infant Health-Related Quality of Life Instrument
Ruslan Jabrayilov et al.
VALUE IN HEALTH (2019)
RSV hospitalization in infancy increases the risk of current wheeze at age 6 in late preterm born children without atopic predisposition
Koos Korsten et al.
EUROPEAN JOURNAL OF PEDIATRICS (2019)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Ting Shi et al.
LANCET (2017)
Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015
Christopher Troeger et al.
LANCET INFECTIOUS DISEASES (2017)
Health Utility Values Associated with Surgical Site Infection: A Systematic Review
Adrian Gheorghe et al.
VALUE IN HEALTH (2015)
A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children, Part II: Evaluation of Psychometric Performance of English-Language Versions in a General Population
Astrid Janssens et al.
VALUE IN HEALTH (2015)
A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children, Part I: Descriptive Characteristics
Astrid Janssens et al.
VALUE IN HEALTH (2015)
Disability weights for the Global Burden of Disease 2013 study
Joshua A. Salomon et al.
LANCET GLOBAL HEALTH (2015)
Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales
Kamran A. Khan et al.
PHARMACOECONOMICS (2014)
The impact of influenza-like illness in young children on their parents: a quality of life survey
Maria Yui Kwan Chow et al.
QUALITY OF LIFE RESEARCH (2014)
Respiratory Syncytial Virus-Associated Hospitalizations Among Children Less Than 24 Months of Age
Caroline Breese et al.
PEDIATRICS (2013)
Respiratory syncytial virus immunization program for the United States: Impact of performance determinants of a theoretical vaccine
Stephane A. Regnier
VACCINE (2013)
Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States
Leonard B. Weiner et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Evidence for a causal relationship between respiratory syncytial virus infection and asthma
Pingsheng Wu et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2011)
The Burden of Respiratory Syncytial Virus Infection in Young Children
Caroline Breese Hall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease
Nahed O. ElHassan et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2006)
The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery
NK Leidy et al.
PEDIATRICS (2005)
Economic analysis of palivizumab in infants with congenital heart disease
LE Yount et al.
PEDIATRICS (2004)
Share Paper
